Baxter International, Inc. (BAX) Tops Q2 EPS by 3c; Guides Q3, FY13 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St turns lower as crude spikes, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts BAX Hot Sheet
Price: $23.93 -0.17%
EPS Growth %: -24.6%
Financial Fact:
Other expense, net: 44M
Today's EPS Names:
PKE, BYRN, HELE, More
EPS Growth %: -24.6%
Financial Fact:
Other expense, net: 44M
Today's EPS Names:
PKE, BYRN, HELE, More
Join SI Premium – FREE
Baxter International, Inc. (NYSE: BAX) reported Q2 EPS of $1.16, $0.03 better than the analyst estimate of $1.13. Revenue for the quarter came in at $3.67 billion versus the consensus estimate of $3.7 billion.
Sees Q3 2013 EPS of $1.18-$1.21, versus the consensus of $1.18.
Sees FY2013 EPS of $4.62-$4.70, versus the consensus of $4.65.
For earnings history and earnings-related data on Baxter International, Inc. (BAX) click here.
Sees Q3 2013 EPS of $1.18-$1.21, versus the consensus of $1.18.
Sees FY2013 EPS of $4.62-$4.70, versus the consensus of $4.65.
For earnings history and earnings-related data on Baxter International, Inc. (BAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Potential Starbucks-Chipotle merger: major opportunity or expensive distraction?
- Aegon shareholders approve US redomiciliation at EGM
- Biofrontera files sNDA to expand Ameluz use to full-body skin lesions
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
